866-997-4948(US-Canada Toll Free)

H3N2 Infection - Pipeline Review, H1 2014

Published By :

Global Markets Direct

Published Date : Apr 2014

Category :

Diseases & Conditions

No. of Pages : 58 Pages


This report provides comprehensive information on the therapeutic development for H3N2 Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H3N2 Infection and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of H3N2 Infection
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
  • The report reviews key players involved in the therapeutics development for H3N2 Infection and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the H3N2 Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the H3N2 Infection pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for H3N2 Infection
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding H3N2 Infection pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
H3N2 Infection Overview 7
Therapeutics Development 8
Pipeline Products for H3N2 Infection - Overview 8
Pipeline Products for H3N2 Infection - Comparative Analysis 9
H3N2 Infection - Therapeutics under Development by Companies 10
H3N2 Infection - Therapeutics under Investigation by Universities/Institutes 12
H3N2 Infection - Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
H3N2 Infection - Products under Development by Companies 15
H3N2 Infection - Products under Investigation by Universities/Institutes 16
H3N2 Infection - Companies Involved in Therapeutics Development 17
Autoimmune Technologies, LLC 17
Takeda Pharmaceutical Company Limited 18
NanoViricides, Inc. 19
Colby Pharmaceutical Company 20
Obio Pharmaceutical Holdings Limited 21
Vaxart, Inc. 22
H3N2 Infection - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Combination Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
BPZE1 Vaccine - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
NV-INF-2 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
TG-21 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Influenza VLP Vaccine - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Flufirvitide-3 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
JVRS-100 + Universal Influenza Vaccine - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
NV-INF-1 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
ID-38 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
C-05 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Gamma-Flu - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
H3N2 Seasonal Influenza Vaccine - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
H3N2 Infection - Recent Pipeline Updates 46
H3N2 Infection - Dormant Projects 53
H3N2 Infection - Discontinued Products 54
H3N2 Infection - Product Development Milestones 55
Featured News & Press Releases 55
Dec 21, 2012: Sarepta Therapeutics Enters Into Clinical Trial Agreement With NIH For Further Development Of Influenza Drug AVI-7100 55
Oct 09, 2012: NanoViricides\'s Oral FluCide Drug Candidate Found To Be Superior To Oseltamivir In Reduction Of Virus Load And Lung Damage Pathology In Animal Models With H3N2 Influenza 55
Jul 26, 2012: Novartis Begins Shipment Of Fluvirin Seasonal Influenza Vaccine In US For 2012-2013 Influenza Season 56

Appendix 57
Methodology 57
Coverage 57
Secondary Research 57
Primary Research 57
Expert Panel Validation 57
Contact Us 58
Disclaimer 58

List of Table


Number of Products under Development for H3N2 Infection, H1 2014 8
Number of Products under Development for H3N2 Infection - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 11
Number of Products under Investigation by Universities/Institutes, H1 2014 12
Comparative Analysis by Clinical Stage Development, H1 2014 13
Comparative Analysis by Early Stage Development, H1 2014 14
Products under Development by Companies, H1 2014 15
Products under Investigation by Universities/Institutes, H1 2014 16
H3N2 Infection - Pipeline by Autoimmune Technologies, LLC, H1 2014 17
H3N2 Infection - Pipeline by Takeda Pharmaceutical Company Limited, H1 2014 18
H3N2 Infection - Pipeline by NanoViricides, Inc., H1 2014 19
H3N2 Infection - Pipeline by Colby Pharmaceutical Company, H1 2014 20
H3N2 Infection - Pipeline by Obio Pharmaceutical Holdings Limited, H1 2014 21
H3N2 Infection - Pipeline by Vaxart, Inc., H1 2014 22
Assessment by Monotherapy Products, H1 2014 23
Assessment by Combination Products, H1 2014 24
Number of Products by Stage and Target, H1 2014 26
Number of Products by Stage and Mechanism of Action, H1 2014 28
Number of Products by Stage and Route of Administration, H1 2014 30
Number of Products by Stage and Molecule Type, H1 2014 32
H3N2 Infection Therapeutics - Recent Pipeline Updates, H1 2014 46
H3N2 Infection - Dormant Projects, H1 2014 53
H3N2 Infection - Discontinued Products, H1 2014 54

List of Chart

Number of Products under Development for H3N2 Infection, H1 2014 8
Number of Products under Development for H3N2 Infection - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Early Stage Products, H1 2014 14
Assessment by Monotherapy Products, H1 2014 23
Number of Products by Top 10 Target, H1 2014 25
Number of Products by Stage and Top 10 Target, H1 2014 26
Number of Products by Top 10 Mechanism of Action, H1 2014 27
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 28
Number of Products by Top 10 Route of Administration, H1 2014 29
Number of Products by Stage and Top 10 Route of Administration, H1 2014 30
Number of Products by Top 10 Molecule Type, H1 2014 31
Number of Products by Stage and Top 10 Molecule Type, H1 2014 32

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *